Craig Hallum Raises Delcath Systems (NASDAQ:DCTH) Price Target to $21.00

Delcath Systems (NASDAQ:DCTH) had its target price boosted by investment analysts at Craig Hallum from $18.00 to $21.00 in a research note issued to investors on Friday,Benzinga reports. The brokerage currently has a “buy” rating on the stock. Craig Hallum’s price objective points to a potential upside of 46.75% from the stock’s previous close.

DCTH has been the topic of a number of other reports. HC Wainwright reaffirmed a “buy” rating and issued a $22.00 target price on shares of Delcath Systems in a report on Tuesday, January 14th. Canaccord Genuity Group reaffirmed a “buy” rating and issued a $21.00 price objective on shares of Delcath Systems in a research note on Friday, October 18th. Stephens reaffirmed a “buy” rating on shares of Delcath Systems in a research report on Friday, October 18th. Finally, StockNews.com upgraded shares of Delcath Systems from a “sell” rating to a “hold” rating in a research note on Friday, October 25th. One research analyst has rated the stock with a hold rating and four have given a buy rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $22.25.

Delcath Systems Trading Up 4.7 %

DCTH opened at $14.31 on Friday. The company has a market cap of $457.49 million, a price-to-earnings ratio of -10.60 and a beta of 0.87. The company’s 50 day moving average is $11.48 and its 200 day moving average is $9.92. Delcath Systems has a 12-month low of $3.70 and a 12-month high of $14.47.

Hedge Funds Weigh In On Delcath Systems

Several large investors have recently made changes to their positions in the business. Polar Asset Management Partners Inc. bought a new stake in Delcath Systems during the 3rd quarter valued at approximately $1,594,000. Shellback Capital LP purchased a new stake in Delcath Systems during the 2nd quarter valued at approximately $1,353,000. Principal Financial Group Inc. bought a new stake in shares of Delcath Systems during the third quarter valued at approximately $808,000. Renaissance Technologies LLC purchased a new position in shares of Delcath Systems in the second quarter worth $694,000. Finally, Cubist Systematic Strategies LLC bought a new position in shares of Delcath Systems during the second quarter worth $370,000. 61.12% of the stock is currently owned by hedge funds and other institutional investors.

About Delcath Systems

Delcath Systems, Inc, an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company’s lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects.